Janux Therapeutics Inc Total Assets
Janux Therapeutics Inc total assets. Based on the latest financial reports, Janux Therapeutics Inc (JANX) holds total assets worth $1.03 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Janux Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Janux Therapeutics Inc (2019–2025)
Total assets of Janux Therapeutics Inc from 2019 to 2025. This chart illustrates how Janux Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Janux Therapeutics Inc (JANX) share price today for real-time trading data and today's change.
Janux Therapeutics Inc - Asset Composition Analysis
Janux Therapeutics Inc Total Assets Breakdown (December 2025)
Janux Therapeutics Inc total assets breakdown as of December 2025. Janux Therapeutics Inc's total assets of $1.03 Billion consist of 96.9% current assets and 3.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.2% |
| Accounts Receivable | $6.43 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Janux Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore JANX net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Janux Therapeutics Inc's current assets represent 96.9% of total assets in 2025, a decrease from 96.9% in 2019.
- Cash Position: Cash and equivalents constituted 5.2% of total assets in 2025, down from 96.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Janux Therapeutics Inc Competitors by Total Assets
Key competitors of Janux Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Janux Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.01 | 58.47 | 43.09 |
| Quick Ratio | 17.01 | 58.47 | 43.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $943.13 Million | $1.01 Billion | $387.40 Million |
Janux Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Janux Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.92 |
| Latest Market Cap to Assets Ratio | 0.87 |
| Asset Growth Rate (YoY) | -5.1% |
| Total Assets | $1.01 Billion |
| Market Capitalization | $878.78 Million USD |
Valuation Analysis
Near Book Valuation: The market values Janux Therapeutics Inc's assets close to their book value (0.87x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Janux Therapeutics Inc's assets decreased by 5.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Janux Therapeutics Inc (2019–2025)
The table below shows the annual total assets of Janux Therapeutics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.01 Billion | -5.09% |
| 2024-12-31 | $1.06 Billion | +179.05% |
| 2023-12-31 | $380.41 Million | +4.50% |
| 2022-12-31 | $364.01 Million | -4.16% |
| 2021-12-31 | $379.82 Million | +2242.13% |
| 2020-12-31 | $16.22 Million | +2288.37% |
| 2019-12-31 | $679.00K | -- |
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in… Read more